

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W., SUITE 600
WASHINGTON, D.C. 20005-3934

www.skgf.com

PHONE (202) 371-2600 FAXSIMILE (202) 371-2540

U.S. Patent and Trademark Office
ROBERT GREENE STERNE
EDWARD J. KESSLER
GEORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
ERIC K. STEFFE
MICHAEL Q. LEE

STEVEN R. LUDWIG
JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.
DONALD R. MCPHAIL
PATRICK E. GARRETT
STEPHEN G. WHITESIDE
JEFFREY T. HELVEY*

HEIDI L. KRAUS
JEFFREY R. KURIN
RAYMOND MILLIEN
PATRICK D. O'BRIEN
LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES*
EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWIT
PETER A. JACKMAN
MOLLY A. McCALL
TERESA U. MEDLER

JEFFREY S. WEAVER
KRISTIN K. VIDOVICH
KENDRICK P. PATTERSON
DONALD J. FEATHERSTONE
GRANT E. REED
VINCENT L. CAPUANO
JOHN A. HARROUN*
MATTHEW M. CATLETT*
NATHAN K. KELLEY*
ALBERT J. FASULO II*
W. BRIAN EDGE*

KAREN R. MARKOWICZ**
SUZANNE E. ZISKA**
BRIAN J. DEL BUONO**
ANDREA J. KAMAGE**
NANCY J. LEITH**
TARJA H. NAUKKARINEN**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

JC914 U.S. PTO
09/688371
10/12/00

October 12, 2000

WRITER'S DIRECT NUMBER:
(202) 371-2625

INTERNET ADDRESS:
ESTEFFE@SKGF.COM

Commissioner for Patents
Washington, D.C. 20231

Box Patent Application

Re: U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)
Appl. No. To be assigned; Filed: Herewith
For: **Recombinant, Replication Defective CELO Virus and CELO Virus DNA**
Inventors: Cotten *et al.*
Our Ref: 0652.2150000/EKS/PSC

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. USPTO Utility Patent Application Transmittal Form PTO/SB/05;
2. U.S. Utility Patent Application entitled:

Recombinant, Replication Defective CELO Virus and CELO Virus DNA

and naming as inventors:

Matthew Cotten;
Jolanta Glotzer; and
Anne-Isabelle Michou

the application comprising:

Commissioner for Patents
October 12, 2000
Page 2

- a. specification containing:
 - i. 47 pages of description prior to the claims;
 - ii. 6 pages of claims (40 claims);
 - iii. a one (1) page abstract;
- b. 11 sheets of drawings: (Figures 1A, 1B, 1C, 2-7, 8A, and 8B);
3. 37 C.F.R. § 1.136(a)(3) Authorization to Treat a Reply As Incorporating An Extension of Time (*in duplicate*); and
4. Two (2) return postcards.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This patent application is being submitted under 37 C.F.R. § 1.53(b) without Declaration and without filing fee.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

EKS/PSC:amm
Enclosures

Please type a sign (+) inside this box →

PTO/SB/05 (08-00)

Approved for use through 10/31/2002 OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR § 1.53(b))

Attorney Docket No.		0652.215000/EKS/PSC
First Inventor		Cotten et al.
Title	Recombinant, Replication Defective CELO Virus and CELO Virus DNA	
Express Mail Label No.		

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

- | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17)
<i>(Submit an original, and a duplicate for fee processing)</i></p> <p>2. <input type="checkbox"/> Applicant claims small entity status.
See 37 CFR 1.27.</p> <p>3. <input checked="" type="checkbox"/> Specification [Total Pages 54]
<i>(preferred arrangement set forth below)</i>
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (<i>if filed</i>)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure </p> <p>4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets 11]</p> <p>5. <input type="checkbox"/> Oath or Declaration [Total Pages _____]
 a. <input type="checkbox"/> Newly executed (original or copy)
 b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d))
 <i>(for continuation/divisional with Box 17 completed)</i>
 i. <input type="checkbox"/> DELETION OF INVENTOR(S)
 Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b). </p> <p>6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76.</p> | <p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program
<i>(Appendix)</i></p> <p>8. Nucleotide and/or Amino Acid Sequence Submission
<i>(if applicable, all necessary)</i></p> <p>a. <input type="checkbox"/> Computer Readable Form (CRF)</p> <p>b. Specification Sequence Listing on:
 i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or
 ii. <input type="checkbox"/> paper</p> <p>c. <input type="checkbox"/> Statements verifying identity of above copies</p> |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s))
10. 37 CFR 3.73(b) Statement Power of Attorney
(when there is an assignee)
11. English Translation Document (*if applicable*)
12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
13. Preliminary Amendment
14. Return Receipt Postcard (MPEP 503) (2)
(Should be specifically itemized)
15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. Other: Authorization under 37 C.F.R. § 1.136(a)(3)
 Other: _____

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:


Continuation Divisional Continuation-in-Part (CIP)
Prior application information: Examiner _____ of prior application No: _____ / _____
Group/Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

18. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or Correspondence address below

NAME	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. Attorneys at Law				
ADDRESS	Suite 600, 1100 New York Avenue, N.W.				
CITY	Washington	STATE	DC	ZIP CODE	20005-3934
COUNTRY	USA	TELEPHONE	(202) 371-2600	FAX	(202) 371-2540

NAME (Print/Type)	Eric K. Steffe	Registration No. (Attorney/Agent)	36,688
SIGNATURE			
Date	10/12/00		

Burden Hour Statement: this form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

**Recombinant, Replication Defective CELO Virus and CELO
Virus DNA**

The present application claims the benefit of
EP 99 120 358.9, filed October 13, 1999, which is
5 herein incorporated by reference, and U.S. Appl. No.
60/167,770, filed November 29, 1999, which is herein
incorporated by reference.

The present invention relates to viral vectors and
viral DNA.

10 Adenovirus has been studied for its role in human
disease (25), as a model for many important discoveries
in molecular biology, including mRNA splicing, DNA
replication, transcription and cell transformation
(reviewed in 44) and more recently as a powerful
15 reagent for transient gene expression (12, 46). A
detailed understanding of the adenoviral life cycle is
well established (reviewed in 50). Since the initial
efforts to use adenovirus as a gene transfer vector
(18, 52, 28) the virus has gained in popularity as a
20 vector and a number of methods of generating
alterations in the viral genome to carry novel genes
have been developed (2, 5, 11, 15, 21, 23, 26, 32, 38,
41, 43, 48 reviewed in 31, 49). Because of the ease of
vector construction and purification, and because these
25 vectors have a potent ability to transiently transduce
novel genetic material into a variety of mammalian cell
types in vivo, adenovirus vectors were used extensively
in early efforts at clinical gene therapy.

Unfortunately, several features of the adenovirus type 5 (Ad5) based vectors initially used have limited the success in the initial applications. These included both the host immune response to adenovirus (reviewed 5 in ref. 55) as well as the failure of the virus to efficiently enter certain target cell types (20, 58, 59). Thus, there is now an interest in adenovirus types that could provoke less aggressive host immune responses and could enter target cells with greater 10 efficiency.

A large number of alternate adenovirus serotypes are known and may provide advantages in some applications over Ad5-based vectors. Additional adenoviruses that have recently been modified as vectors include the 15 ovine adenovirus 287 (29, 53, 56,), the bovine adenovirus type 3 (40, 60), and the canine adenovirus (30). It was considered that these alternate serotypes would provide both a novel vector backbone to which there is no pre-existing immune response in the target 20 host. Furthermore, because adenoviruses are extremely species specific in their replication capacity (50) a degree of security against inappropriate vector replication is gained by using a vector derived from a distant species of adenovirus.

25 There are several justifications for pursuing these alternate viral subtypes. For vaccine applications in their non-human hosts, these viruses, if properly modified, may provoke more effective immune responses than a human adenovirus based vector. Furthermore, more 30 robust immune responses might be expected from a replication competent virus; thus a vector is most

useful in a host where replication is partially or fully permissive. This is not the case with human adenovirus based vectors in nearly all nonhuman hosts.

It has been an object of the invention to provide an
5 alternative adenovirus vector for use as a gene delivery vector and for use as a vaccine.

To solve the problem underlying the present invention, the avian adenovirus CELO has been chosen to be modified. CELO (chicken embryo lethal orphan or fowl
10 adenovirus type 1, reviewed in 39) was characterized as an infectious agent in 1957 (57). There are few serious health or economic consequences of CELO virus infection. CELO can be isolated from healthy chickens and in general, do not cause disease when
15 experimentally re-introduced into chickens (10).

CELO virus is structurally similar to the mammalian adenoviruses (mastadenoviruses) with an icosahedral capsid of 70-80 nm made up of hexon and penton structures (33); the CELO virus genome is a linear,
20 double-stranded DNA molecule with the DNA condensed within the virion by virus-encoded core proteins (33, 36). CELO virus has a larger genome than Ad5 (44 kb vs. ca. 36kb, ref. 6, WO 97/40180). The CELO virion has two fibers of different lengths at each vertex (24, 33, 35)
25 rather than the single fiber of most other serotypes (reviewed in 50). The CELO virus is not able to complement the E1A functions of Ad5 and CELO virus replication is not facilitated by Ad5 E1 activity (37). The complete DNA sequence of CELO (6, WO 97/40180)
30 revealed additional differences between CELO virus and

the mastadenoviruses including the absence of sequences corresponding to the Ad5 early regions E1A, E1B, E3 and E4. The CELO genome contains approximately 5 kb of sequence at the left end and 12 kb at the right end,
5 rich in open reading frames, which have no sequence homology to Ad5 but probably encode the early functions of the virus.

When developing CELO into a gene delivery vector, it has been considered that the virus is naturally
10 defective in mammalian cells and this property should limit the possibility of complementation by wildtype mammalian adenovirus. The CELO virion has increased DNA packaging capacity and much greater physical stability than the virion of Ad5. One practical feature of CELO
15 is the ability to grow the virus in chicken embryos, a system of low cost and high convenience (9, 33).

For application in avian systems, especially for vaccine applications, it would be useful to have a CELO derivative with reduced replication capacity. Such a
20 replication defective virus would allow transduction of avian species or avian cells similar to replication competent CELO vectors, but the amplification and spread of the modified virus would be limited by the impaired replication capacity of the virus.

25 A gene termed Gam1 was originally identified in the CELO genome in a search for viral genes that influence cell survival (7). The Gam1 protein is encoded by CELO nucleotides 37391-38239, transcriptional control sequences are located within ca. 1500 basepairs

upstream and ca. 300 basepairs downstream of the coding region.

The present invention relates to recombinant CELO virus or CELO virus DNA that have the region spanning

- 5 nucleotides 37391-38239 of the CELO wild type virus genome completely or partially deleted or altered or that contain an insertion in this region, any of which modifications results in a complete loss of Gaml expression or prevents the expression of a functional
10 Gaml protein. Alternately to a disruption in the region defined above, the virus may contain a disruption in the transcriptional control elements of the Gaml gene.
(For simplicity, any modification that results in a complete loss of Gaml expression or an inhibition of
15 functional Gaml expression will be referred to „Gaml disruption“ in the following.)

The suitability of a CELO mutation for obtaining a virus of the invention can be readily determined by ascertaining the absence of Gaml expression. Suitable

- 20 tests employ standard immunological methods, e.g. immunofluorescence microscopy or Western immunoblotting using antisera specific for the Gaml protein.

The CELO nucleotide sequence numbering used in the present invention is derived from reference 6,

- 25 WO 97/40180 and GenBank U46933, which describe the sequence of the wild type CELO virus genome.

CELO virus or CELO virus DNA with Gaml disruptions, and their derivatives respectively, have been designated CELO AIM65 or CELO AIM65 derivatives, respectively.

In an embodiment, the invention is directed to a CELO AIM65 derivative with a complete or partial deletion and/or insertion within the Gaml gene as defined above.

- 5 Preferably, the nucleotides 37391-38239 are completely deleted to provide more space for inserting the foreign DNA in place of the deletion.

In another preferred embodiment, the deletion comprises the region defined by the restriction sites

- 10 SmaI/Bgl II, i.e. the region spanning nt 36818-37972, which removes part of the Gaml open reading frame.

The deletions defining CELO AIM65 may be combined with mutations defining CELO AIM46 (79) or its derivatives.

Examples for AIM46 mutations are complete or partial

- 15 deletion(s) of the regions spanning nt 41731-43684, 41523-43684, 41002-43684 or 40065-43684. Besides, the CELO AIM65 modifications may also be combined with the modifications described for AIM69 and/or AIM70 (79).

Thus, the CELO virus and CELO virus DNA of the

- 20 invention carry a Gaml disruption that is optionally combined with a deletion spanning approximately the region from nt 40,000 to approximately within 200 bp of the right terminus of the virus genome. The region that may be completely or partially deleted or disrupted is 25 thus defined by the last three rightward open reading frames encoding peptides of greater than 99 amino acid residues, with the terminal repeat function of the virus normally residing within the last 100 - 200 bp of the virus genome remaining undisrupted. Optionally, the 30 CELO virus and CELO virus DNA of the invention may, in

addition, have a deletion in the region defined by the open reading for the CELO dUTPase (794-1330).

Since CELO AIM65 and its derivatives defined above allow the insertion of large pieces of foreign DNA, they are
5 useful as starting material for producing CELO virus vectors.

Apart from allowing the insertion of an expression cassette for genes, the recombinant CELO virus of the invention has been shown to be replication defective in
10 cell culture.

It was a further object of the invention to provide a method for cultivation of the CELO AIM65 virus of the invention.

The disruption in the Gaml gene renders CELO AIM65
15 extensively defective in replication. A study of the biological function of the Gaml gene revealed that Gaml expression leads to increases in the cellular levels of certain heat shock proteins. It was therefore hypothesized that an essential function of Gaml is to
20 upregulate a heat shock response during infection.

Based on this hypothesis, it was tested whether heat shock applied to the infected cell could allow the replication of a CELO derivative lacking the Gaml gene.

Surprisingly it was found that, although the Gaml
25 deletion severely impaired CELO virus replication, the functions of the Gaml gene in virus replication could be provided by exposing the host cells to a heat shock. This novel type of complementation allows to grow

viruses that otherwise are severely defective in their replication capacity.

The invention relates, in a further aspect, to a method for producing CELO AIM65.

- 5 The method comprises the following steps: Cells which support wildtype CELO replication (e.g. LMH cells, ATCC No. CRL-2117) are grown and exposed to a heat shock either before, simultaneously, or after infection with the CELO AIM65 (e.g. 10-1000 particles per cell). Under
10 conditions suitable for cell cultivation and for a period of time sufficient for producing the desired number of viruses, e.g. after cultivation for 4 days at 37°C, lysates of the cells are prepared and virus is prepared by standard methods. The heat shock treatment
15 preferably comprises exposure to temperatures above 43°C, preferably 45°C, for period of time sufficient to complement the replication defect, preferably for 30-120 minutes, most preferably 90 minutes. The optimal conditions can be determined empirically in a routine
20 series of virus growth experiments.

Furthermore, in vivo, in chicken embryos the recombinant CELO virus of the invention is highly defective for replication, i.e. the virus does not replicate when infected at levels below 10^7 particles per embryo,

- 25 however when infected at higher multiplicities, wild type levels of the virus can be obtained. This property facilitates the growth of the defective virus for various applications.

Although replication deficient, the virus of the
30 invention, when used at high multiplicities of infection

in chicken embryos, grows to wildtype levels and forms, as the virus grown in cell culture under heat shock conditions, the basis of a replication-defective vaccine strain.

- 5 Since CELO AIM65 and its derivatives contain the same capsid components as CELO AIM46, CELO AIM65 and its derivatives possess the same ability as CELO AIM46 to introduce genes into a broad range of cell types including, in addition to avian cells, human, bovine, 10 equine, monkey, murine, and canine cell types.

The cells that support CELO virus replication and are thus useful for CELO virus production, may be selected from immortalized cells like LMH (27) or from primary avian embryonic cells, in particular kidney or liver 15 cells. To identify useful cell lines, cells are tested for infectability and the ability to amplify an inoculum of virus after heat shock of the host cell as described below.

Alternatively, once a sufficient stock of the defective 20 virus is obtained from cell culture growth using the heat shock step, the recombinant CELO virus may be produced by introducing CELO virus into chicken embryos at sufficiently high multiplicities (i.e. greater than 10^7 particles per embryo).

- 25 An alternate method of growing CELO AIM65 or its derivatives is based on the observation that Gam1 functions can be partially replaced by overexpressing hsp40 or another gene upregulated by Gam1 in the host cell. Thus replication of AIM65 or derivatives can be 30 obtained by coinfecting the host cells with a

recombinant adenovirus directing the synthesis of hsp40 (e.g. Adhsp40) or by transfecting the host cell with a plasmid encoding hsp40. Alternately, the hsp40 expression can be directed by an hsp40 expression 5 cassette inserted directly in the CELO AIM65 genome (e.g. CELOdGhsp40).

In order to produce recombinant a CELO virus genome with a Gam1 disruption, a plasmid bearing the genomic right end 13.3 kb fragment is modified to delete a portion of 10 the Gam1 coding sequence and an expression cassette, e.g. a BamHI CMV/luciferase/βglobin expression cassette is inserted by standard ligation cloning. This modified region is built into a recombinant CELO genome by homologous recombination to produce a plasmid 15 (designated pAIM65). This modified CELO genome is then released from the plasmid backbone by restriction digest and introduced by transfection into cells that support CELO virus replication. Useful levels of CELO AIM65 virus replication were found to occur only when using 20 heat-shocked LMH cells.

Alternatively, recombination can be performed in avian cells that support AIM65 viral replication, e.g. heat shocked LMH cells, by introducing a modified CELO subfragment that contains a deletion/insertion with a 25 second CELO fragment such that overlapping homology between the two fragments allows recombination to full length CELO genome bearing the desired deletion/insertion.

The replication defective vectors of the invention have 30 vaccine applications in avian species where wildtype

levels of CELO viral replication could produce unwanted toxicity or pathology. The ability to propagate AIM65 derived vectors in inexpensive chicken embryos when inoculated in sufficient quantities or by applying

- 5 appropriate heat shock conditions (which can be determined by routine cultivation assays), facilitates production of large quantities of the vector for any of these applications.

For vaccine applications, the foreign DNA encodes one or
10 more antigens eliciting an immune response in the individual. The antigen may be the natural protein derived from the pathogen, or an immunogenic fragment thereof, e.g. an immunogenic peptide.

- To drive expression of the foreign DNA, an expression
15 cassette can be used, which typically includes a promoter active in the target cells, the cDNA of interest, a polyadenylation signal and optionally an intron. Alternately, the DNA inserted into the modified CELO genome may include endogenous CELO promoters,
20 introns and polyadenylation signals to drive expression of the cDNA of interest.

- An example for a useful expression cassette, which can be prepared by conventional methods, is derived from a plasmid designated pPM7. It contains the
25 Cytomegalovirus (CMV) immediate early enhancer/promoter followed by a short polylinker with PacI, HpaI and KpnI sites, followed by a rabbit β -globin intron/polyadenylation signal. The CMV/ β -globin material may be derived from plasmids available in the art (e.g. from the plasmid pLuc (74), which carries the
30

luciferase gene), modified by PCR to add flanking restriction sites, e.g. BamH1, and subsequently modified by homologous recombination to replace the luciferase cDNA with a PacI/HpaI/KpnI polylinker. The 5 final BamHI cassette can be cloned into pSP65 to generate pPM7. cDNAs to be cloned into CELO AIM65 derivatives are first cloned into pPM7 using the unique 10 restriction sites (PacI/HpaI/KpnI). Subsequently a restriction or PCR fragment, e.g. a BamHI fragment, is prepared containing the CMV promoter/cDNA/β-globin unit 15 which is introduced into PacI linearized pAIM65 by homologous recombination. The CMV and βglobin sequences provide homology for the recombination and the luciferase cDNA is thus replaced with the novel cDNA of interest.

The expression cassettes described above can be modified, e.g. by using, instead of the CMV enhancer/promoter, a variety of other viral or cellular promoters including, but not limited to the SV40 20 enhancer promoter, the Rous Sarcoma Virus long terminal repeat (RSV LTR), the human β-actin promoter, the CELO virus major late promoter, the adenovirus major late promoter, the rat insulin promoter.

Alternatives to to the rabbit β-globins 25 intron/polyadenylation signal include, but are not limited to the intron/polyadenylation signals from SV40, introns and polyadenylation signals from other viruses and from cellular genes could also be used.

Alternately to using an expression cassette, the foreign 30 cDNA may be a simple insert within a region defining

CELO AIM 46 or the deoxyUTPase, thus using endogenous CELO regulatory sequences, e.g promotor, intron, polyadenylation signal.

In the case that two different foreign cDNAs are to be expressed from the CELO vector, e.g. cDNAs encoding two different antigens from a pathogen, the following strategies may be used: in a first embodiment, two gene expression cassettes (carrying different cDNAs and different regulatory sequences) can be inserted into the CELO genome. Alternately, an internal ribosome entry site (IRES) can be used to provide expression from two cDNAs using a single promoter, as described by e.g. 70; 67; 71; 72. Thus, a typical expression cassette for CELO AIM65 carrying two cDNAs to be expressed, includes a promoter, the first cDNA, an IRES, and the second cDNA followed by an optional intron and by a polyadenylation signal.

The foreign cDNA, e.g. antigen cDNA, can be isolated from the genomes of the pathogens by standard methods, 20 e.g. by PCR or by restriction digest, optionally including reverse transcription to convert RNA to DNA, and introduced into a transfer vector carrying the regulatory sequences and unique restriction sites, e.g. the pPM7. Subsequently, this antigen expression unit a 25 recombined into a linearized plasmid bearing the CELO genome and having the same regulatory sequences and corresponding restriction sites, e.g. the plasmid pAIM65. The resulting CELO-AIM65 vector, carrying the antigen cDNA, can be grown and purified from chicken embryos.

Examples for antigens useful for vaccine applications are given in WO 97/40180, which is fully incorporated by reference herewith.

Further examples for antigens that may be carried by
5 the virus for vaccination applications are antigens of the infectious bursal disease virus (IBDV; 64) and antigens of Chicken coccidia, e.g. *Eimeria acervulina*, *Eimeria brunetti*, *Eimeria maxima*, *Eimeria mitis*, *Eimeria necatrix*, *Eimeria praecox* and *Eimeria tenella*
10 (61, 62, 63), examples for antigens are a parasite refractile body transhydrogenase, lactate dehydrogenase, Ea1A and EaSC2 (reviewed in 77).

Further examples for antigens are the glycoprotein C (gC, glycoprotein gIII) of the porcine pathogen
15 pseudorabies virus (the causative agent of Aujeszky's disease (75; 76; 69). A CELO AIM46 vector carrying gC can be used to elicit an anti--pseudorabies response in pigs.

A robust immune response is to be expected from a
20 replication competent virus. However, under certain conditions, the replication of CELO derived vectors (e.g AIM46 vectors) may produce unsuitable levels of pathology in the host. Therefore, the replication defective vectors of the current invention may be
25 useful at limiting the spread of the vaccine without compromising the initial entry and gene expression from the vector in the host. In this regard, the CELO vectors of the present invention, CELO AIM65 and its derivatives, are ideally suited for avian vaccine
30 applications.

The recombinant CELO virus vectors of the invention are also useful in human vaccine or gene transfer applications. Wild type CELO is replication defective in mammalian cells, therefore the additional replication

5 block generated by the removal of Gaml expression provides further measure of security. Furthermore, the removal of Gaml expression will lower the amount of background gene expression from the vector which may have unpredictable effects on the host cell or organism.

10 An additional argument for pursuing a non-human adenovirus comes from the experience with human adenovirus in human gene transfer applications. Pre-existing immune responses to human adenovirus can impair the initial transduction by human adenovirus

15 based vectors or might exacerbate the cellular immune response to transduced cells. A patient may have no immune experience with an adenovirus from a distant species (although 2 of 7 patients had neutralizing antibodies to the canine adenovirus vector; 30) and

20 initial transductions will not be compromised by the host response to viral antigens. Except for certain agricultural workers, a previous immune exposure to CELO antigens would not be expected in most of the human population. CELO vectors might therefore have an
25 advantage over vectors based on more common human adenovirus serotypes.

An additional conceptual advantage of CELO based vectors of the invention is that CELO, like the bovine, ovine, and canine adenoviruses, is naturally replication
30 defective in human cells. Thus, replication of these

vectors will not occur in human patients even in the presence of a wildtype human adenovirus infection.

For gene therapy applications, the foreign DNA may comprise any one or more DNA molecules encoding a therapeutically active protein. Examples are immunomodulatory proteins like cytokines; receptors, enzymes, proteins effecting apoptosis, proteins modulating angiogenesis, e.g. sFLT, FGF receptors, etc.

For tumor vaccine applications, the foreign DNA encodes one or more tumor antigens or fragments thereof, preferably in combination with a cytokine.

Examples for human vaccine applications, gene therapy and tumor vaccine applications are given in WO 97/40180, which is fully incorporated by reference herewith.

For vaccine applications, the vector of the invention may be packaged as an enteric coated dosage unit, or in an injectable form for intramuscular, intraperitoneal or subcutaneous injection. Alternately, the vector may be administered as a paste or a fluid intranasally or intratracheally, as an aerosol or as an intraocular drop. The vector may also be supplied incorporated in feed pellets or in the drinking water.

The quantity of virus introduced per patient, animal or egg may range from 1 to 10^{12} particles.

The virus preparation may include a physiological buffered saline or HEPES buffered saline and may optionally be mixed with adjuvants such as vitamin-E acetate, oil/water emulsion, aluminium hydroxide,

-phosphate or -oxide, mineral oil emulsions such as Bayol^(R) or Marcol 52^(R) and saponins.

- It may be useful to use a freeze-dried form of the virus as a vaccine (78). The inclusion of a stabilizer such as
- 5 10% sucrose may be used with a controlled two-step drying process(78). Alternative stabilizers include carbohydrates such as sorbitol, mannitol, trehalose, starch, sucrose, dextran or glucose, proteins such as albumin or casein, or their degradation products.
- 10 In vaccine applications, in order to enhance the host immune response, the immune response elicited by the application of the CELO vaccine vector that carries a specific antigen, can be boosted by additionally administering the same antigen or an immunogenic fragment
- 15 thereof. Preferably, the additionally administered antigen is recombinant; it can be obtained by standard methods or by the method described below that uses CELO vectors to obtain the recombinant proteins from eggs. The combined application of the vector and the antigen
- 20 can be performed as described by (65, 73). Preferably, the recombinant antigen is administered, optionally together with an immunostimulating adjuvant, subsequent to the CELO vector.
- In a further aspect of the invention, CELO virus is used
- 25 for producing any protein of interest.
- CELO AIM65 derivatives may have advantages over replication-competent CELO virus derivatives in that toxicity produced by the virus replication could limit protein production. Cells or embryos infected with AIM65
- 30 derivatives are expected to survive longer than cells or

embryos infected with replication competent CELO derivative and thus, the production of recombinant proteins encoded by AIM65 derivatives is expected to be higher.

- 5 In this embodiment of the invention, the CELO virus, e.g. CELO AIM65 or its derivatives, is engineered, as described above, by introducing the cDNA or, preferably, an expression cassette, encoding the protein of interest into one of the insertion sites of the recombinant CELO
 - 10 DNA of the invention. Virus may be obtained by replication in suitable cells, as described above, and the recombinant virus is introduced, preferably by injection into the allantoic cavity of an avian embryo. Preferably, approximately 4×10^7 particles are introduced
 - 15 into the allantoic cavity of 7 to 9 day old chicken embryos, which are subsequently incubated for three to four days at 37°C. The recombinant material is then recovered from the allantoic fluid, serum, yolk, amniotic fluid or from the embryo itself.
 - 20 The protein of interest may be an intracellular or a secreted protein. In the case of a intracellular protein, the protein can be recovered by lysing infected cells that accumulate in the allantoic fluid. In the case of a secreted protein, the material can be
 - 25 recovered from various extracellular fluids of the embryo (allantoic fluid, amniotic fluid, serum, yolk) or, in analogy to the recovery of intracellular proteins, by lysing infected cells.
- In a preferred embodiment, the protein of interest is
- 30 expressed as a fusion protein comprising the protein

and, as a stabilizing sequence, an immunoglobulin Fc domain. The secretion of the recombinant protein can be directed by the natural signal sequence from the protein, which may, in addition to the signalling function, have a stabilizing function. The Fc domain confers stability to the protein in the extracellular space and provides a protein sequence that can be used for affinity purification of the recombinant protein using, for example, Protein A or Protein A/G chromatography resins. Constructs that include an Fc domain for stabilization and are thus useful to be expressed from CELO, have been employed to make soluble forms of the FGF receptor 2 (sFGFr; 66) and the VEGF receptor 1 (sFLT; 68).

As alternatives to the signal sequences of FLT and the FGF receptor, signal sequences from or fusions with the proteins ovalbumin, conalbumin, avidin and lysozyme can be used. These are proteins that are synthesized in the liver and/or oviduct of chickens and accumulate within the egg. Thus, using part or all of the coding sequence of these proteins fused to a protein of interest are expected to yield secreted recombinant proteins that are stable within the developing embryo; furthermore, using sequences of this type, e.g. avidin, provides a tag that facilitates chromatographic purification.

Brief description of the Figures:

Figure 1. Demonstration that Gaml expression elevates heat shock protein levels.

Figure 2. Gam1 expression relocates hsp70 to the nucleus in the absence of heat.

Figure 3. Analysis of the subcellular localization of hsp70 and hsp40.

5 Figure 4. Hsp70 is upregulated during CELO infection.

Figure 5. Analysis of CELO AIM65 growth and complementation with AdGam1.

Figure 6. Analysis of CELO AIM65 growth in chicken embryos.

10 Figure 7. Complementation of CELO AIM65 growth by heat shock.

Figure 8. Complementation of CELO AIM65 growth by heat shock in a single round of infection.

8a: CELO capsid protein production.

15 8b: Generation of infectious CELO particles.

Unless otherwise stated, the following materials and methods were used in the Examples:

20 a) Generation of a recombinant a CELO virus genome with a disrupted Gam1 gene

In order to produce recombinant a CELO virus genome with a disrupted Gam1 gene, a plasmid bearing the genomic right end 13.3 kb fragment (pB13.3) (the

25 sequence from the Hpa I site at nt 30502 until the

right end terminal repeat/ligated to an SpeI site cloned into pBluescript) was digested with the restriction enzymes BglII and SmaI, and the BamHI CMV/luciferase/βglobin expression cassette was inserted
5 by standard ligation cloning. This removed the region from nt 36818 to 37972, including the first part (581 bp) of the Gaml coding sequence and produced the plasmid pAIM55 containing a disrupted Gaml coding sequence. A Mlu I, SwaI fragment from pAIM55 was
10 introduced into pWÜHpa (digested with XhoI; 79) using homologous recombination in *E coli* BJ5183 (5, 13) to produce pAIM62, which was subsequently linearized with HpaI and used to recombine with wildtype CELO DNA to produce pAIM65. All manipulations were confirmed by
15 restriction analysis and sequence analysis. The CELO nucleotide sequence numbering is derived from reference 6 and GenBank U46933.

b) Generation of CELO virus expressing luciferase

The luciferase cassette containing the Cytomegalovirus
20 immediate early enhancer/promoter, the luciferase cDNA (14) followed by a rabbit βglobin intron/polyadenylation signal was derived from pCLuc (45), modified by PCR to add flanking BamH1 sites and cloned into pBlueScript II (SK) to generate pBlueLuc.
25 For most of the CELO insertions, the luciferase cassette was isolated from pBlueLuc by BamH1 digestion and the termini were made blunt by treatment with Klenow enzyme.

c) Generation of recombinant type 5 adenovirus

right end terminal repeat/ligated to an SpeI site cloned into pBluescript) was digested with the restriction enzymes BglII and SmaI, and the BamHI CMV/luciferase/βglobin expression cassette was inserted
5 by standard ligation cloning. This removed the region from nt 36818 to 37972, including the first part (581 bp) of the Gaml coding sequence and produced the plasmid pAIM55 containing a disrupted Gaml coding sequence. A Mlu I, SwaI fragment from pAIM55 was
10 introduced into pWÜHpa (digested with XbaI; 79) using homologous recombination in *E coli* BJ5183 (5, 13) to produce pAIM62, which was subsequently linearized with HpaI and used to recombine with wildtype CELO DNA to produce pAIM65. All manipulations were confirmed by
15 restriction analysis and sequence analysis. The CELO nucleotide sequence numbering is derived from reference 6 and GenBank U46933.

b) Generation of CELO virus expressing luciferase

The luciferase cassette containing the Cytomegalovirus immediate early enhancer/promoter, the luciferase cDNA (14) followed by a rabbit βglobin intron/polyadenylation signal was derived from pCLuc (45), modified by PCR to add flanking BamH1 sites and cloned into pBlueScript II (SK) to generate pBlueLuc.
25 For most of the CELO insertions, the luciferase cassette was isolated from pBlueLuc by BamH1 digestion and the termini were made blunt by treatment with Klenow enzyme.

c) Generation of recombinant type 5 adenovirus
30 expressing Gaml

The Gam1 coding sequence (nt 37391-38239 in the CELO genome) plus an amino terminal myc tag were amplified from pSG9mGam1 (7) and modified to contain terminal Pac1/Kpn1 restriction sites using PCR. The fragment was
5 transferred into an E1/E3 negative adenovirus 5 genome using homologous recombination in bacteria (5, 79). The final virus bears an expression unit containing a CMV promoter, the myc-tagged Gam1 coding sequence and rabbit β -globin intron polyA signal embedded in the E1 region.
10 Control E1-negative Ad5 viruses expressing luciferase (AdLuc), eGFP (AdGFP) or β galactosidase (AdRSV β gal) and their purification on CsCl gradients have been described previously (79, 80).

15 d) Generation of recombinant adenovirus type5 and CELO virus expressing human hsp40 or human hsp70

Adhsp40, Adtethsp70: The hsp40 cDNA was amplified from a human hsp40 cDNA plasmid (Ohtsuka, 1993) using PCR and transferred into an E1/E3 negative adenovirus 5 genome using homologous recombination in bacteria (Chartier et al., 1996; Michou et al., 1999). The final 20 virus bears an expression unit containing a CMV promoter, the hsp40 coding sequence and rabbit β -globin intron polyA signal embedded in the E1 region. Similar methods were used to construct an adenovirus bearing a human hsp70 coding sequence Hunt and Morimoto, 1985).
25

The CELOdGhsp40 and CELOdGhsp70 genomes were constructed by exchanging the CMV/luciferase/ β -globin cassette in pAIM65 for CMV/hsp40/ β -globin or CMV/hsp70/ β globin cassettes.

- e) Evaluation of the recombinant CELO genomes on LMH cells and preparation of viral stocks.

The recombinant CELO plasmids were digested with SpeI
5 to release the viral genome from the plasmid, extracted
with phenol, with chloroform and then purified by gel
filtration (Pharmacia Nick Column) equilibrated
with TE.

Transfection complexes were prepared using a
10 modification of the PEI technique (1, 3, 79). The DNA
was condensed with PEI in two steps as follows: PEI
MW 2000 (2.5 μ l of 10 mM PEI in 125 μ l HBS (150 mM
NaCl, 20 mM HEPES, pH 7.4)) was added dropwise to 3 μ g
of DNA diluted in 125 μ l of HBS. The sample was
15 incubated at room temperature for 20 minutes.

Subsequently, PEI MW 25000 (3.5 μ l of 10 mM in 125 μ l
of HBS) was added dropwise to the sample and the
complex incubated at room temperature for an additional
20 minutes.

20 Leghorn Male Hepatoma (LMH) cells (27) were seeded the
day before transfection in 24 wells plates at 7×10^4
cells/well (24 well dish). For transfection, the cell
culture medium was replaced by 400 μ l DMEM. The
transfection complex (90 μ l per well) was added to the
25 cells for 4 hours at 37°C after which the medium was
replaced with fresh, 10% fetal calf serum containing
medium. In one set of samples (indicated by +AdGm1) an
aliquot of AdGm1 (1000 particles per cell) was added
24 hours later. After 5 days the cells were harvested
30 and assayed for luciferase activity (=Passage 0). An

additional culture was used to infect a fresh set of LMH cultures either alone, or with the addition of AdGaml as before. Thus, cleared lysates from transfected cells were prepared as follows. Cells plus supernatant were harvested, collected by centrifugation and the cell pellets were resuspended in 2 ml of processed supernatant. The material was frozen and thawed 3 times, sonicated in a bath sonicator to release viral particles, the cell debris was removed by centrifugation, and the cleared lysate used for further amplification on fresh cultures of LMH cells. The harvest, luciferase assay and passage were repeated every 5 days for 5 passages. Figure 2 left panel: CELO AIM65 (CELOΔG) alone; right panel: CELO AIM65 (CELOΔG) plus AdGaml. The luciferase activity (average of three cultures plus standard deviation) is indicated for each passage.

f) Cell Fractionation

Cell pellets were suspended in buffer A and lysed by passage through a 21 ga. needle. Nuclei were harvested by centrifugation (large scale HBS rotor, 20 minutes, 8 K) small scale 5 minutes eppendorf, 10,000 x g. The cytoplasmic supernatant (C) was removed and the pellet was gently resuspended in buffer B. The suspension was again centrifuged to yield the supernatant nuclear extract (N1) and the pelleted, extracted nuclei (N2).

Buffer A: 20 mM HEPES, pH 7.4, 0.5 M sucrose, 50 mM NaCl, 1 mM EDTA, 0.25 mM EGTA, 0.5 mM spermidine, 0.15 mM spermine, 0.5% Triton X-100, 7 mM β-mercaptoethanol, protease inhibitor cocktail (Sigma).

Buffer B: 20 mM HEPES, pH 7.4, 25% glycerol, 100 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.5 mM spermidine, 0.15 mM spermine, 7 mM β -mercaptoethanol, protease inhibitor cocktail (Sigma).

5 g) Immunoblotting analysis

A549 cells were lysed in lysis buffer (150 mM NaCl, 50 mM Tris, pH 7.5, 5 mM EDTA, 1% NP-40 containing protease inhibitor cocktail (Sigma)). Cells were agitated at 4°C for 30 minutes, passaged through a 10 25 ga. needle 5 times, sonicated in a bath sonicator for 5 minutes, centrifuged 14,000 RPM (Eppendorf) for 5 minutes and the supernatant was used for immunoblotting analysis. Equal quantities of protein (measured by Bradford reagent, Pierce) were resolved by 15 PAGE, transferred to nitrocellulose and probed with the indicated antiserum preparations (see below). Antibody binding was revealed using the appropriate peroxidase-conjugated secondary antibodies (Dako) and ECL reagents (Amersham).

20 h) Immunofluorescence

Cells were plated on glass cover slips (12x12mm) in 6 well dishes 24 hours before infection. Cells were fixed one day after infection in 4% paraformaldehyde for 15 min, rinsed 3 times with PBS, permeabilized with 25 PBS/0.1% Triton X-100 (PBT) for 15 min, blocked in 5% BSA/PBT for 30-60 min, incubated with primary antibody for 15 min in 5% BSA/PBT, washed 3 times with PBT, incubated with secondary antibody for 15 min in 5% BSA/PBT, washed 2 times with PBT, 2 times with PBS 30 and mounted in 50% glycerol/PBS, 10mM Tris pH 8.5,

4% n-propyl gallate (Sigma); all incubations were done at room temperature. DNA was stained with Hoescht dye. Images were acquired with a cooled CCD camera (Spot II; Diagnostic Instruments) mounted on an Axiovert 5 microscope (Zeiss) and equipped with 63x/1.4 lens; with filters from Chroma Tech. and processed using Adobe Photoshop software.

Antiserum preparations used were a murine monoclonal 9E10 recognizing the myc epitope (81) murine 10 monoclonal, RPN-1197 recognizing hsp70 (Amersham) or goat polyclonal sera recognizing hsp70, hsp40, hsp90a, hsc70 and hsp27 (Santa Cruz Biotechnology), anti-tubulin (clone DM1A, Sigma) and a rabbit polyclonal directed against total capsid proteins (79). Secondary 15 antibodies were a DTAF conjugated donkey anti mouse, DTAF conjugated donkey anti rabbit, Cy3 conjugated donkey anti goat (Jackson Laboratories), all were used at 1:100 dilutions.

j) Additional reagents

20 CELO AIM46 was purified from either LMH cultures or infected chicken embryos as previously described (9, 79).

The LMH cell line (27) was obtained from ATCC No. CRL-2117, the A549 cell line was also obtained from 25 the ATCC No. CCL-185, both cell types were cultured in DMEM/10% FCS.

The 293 cell line (19) was obtained from the ATCC (No. CRL-1573) and was cultured in MEMalpha with 10% newborn calf serum.

Example 1

Gam1 expression from a recombinant virus elevates hsp70 and hsp40 levels.

- 5 To analyze the cellular response to Gam1, an E1-defective adenovirus type 5 vector expressing a myc epitope tagged Gam1 protein was constructed (AdGam1).

In the experiments shown in Figure 1a, extracts from A549 cells that were either transfected with a plasmid

- 10 encoding a myc-tagged E1B 19K gene (lane 1) or myc-tagged Gam1 (lane 2 and 3) or infected with AdGam1 at 300, 3000 or 30,000 particles /cell (lanes 4, 5, 6) were analyzed by immunoblotting using an antibody against the myc epitope (81).

- 15 It becomes clear from Fig. 1a that AdGam1 directs substantial levels of Gam1 expression in 80-100% of the cells exposed to the virus (see Fig. 2).

To determine if Gam1 expression influences hsp70 protein levels, A549 cells were infected with either

- 20 AdGam1 or a control adenovirus encoding nuclear targetted β -galactosidase (Ad β gal). In the experiments shown in Figure 1b, as in Figure 1a, cells were infected with the indicated adenovirus; heat shock (43° for 90 minutes) was applied as indicated, 24 hours
25 later. Cells were harvested 48 hours post-infection, extracts were prepared, equal quantitites of protein were resolved by SDS-PAGE and either stained with Coomassie blue (left panel) or analyzed by immunoblotting for hsp70 (right panel). Extracts from

non-infected cells (lane 2); cells infected with control adenovirus (Ad β gal) at 1000 (lanes 3, 9) or 10,000 particles per cell (lanes 4, 10) or with AdGaml at 100 (lanes 5, 11) 1000 (lanes 6, 12) or 10,000 5 particles per cell (lanes 7, 13); no heat shock (lanes 2-7); heat shock (lanes 8-13).

Both virus-encoded transgene products were highly expressed (Fig. 1b, left panel). A substantial increase in hsp70 protein was observed in cells expressing Gaml 10 (Fig. 1b, right panel). No hsp70 induction was observed in cells expressing similar quantities of nuclear targetted β galactosidase, demonstrating that neither E1-defective adenovirus infection, nor high levels of exogenous protein expression were responsible for the 15 effect. The hsp70 induction was similar to that obtained with heat shock (Fig. 1b, right panel); a modest synergy was observed if both Gaml expression and heat were applied (compare lanes 5-7 to lanes 11-13).

An analysis of the effects of Gaml expression on hsp40 20 levels was performed. In Figure 1c, the infection, heat shock and immunoblotting was as described in Figure 1a. Non-infected cells (lanes 1, 5); cells infected with 10,000 particles/cell control adenovirus (AdLuc; lanes 2, 6); cells infected with 1000 particles per 25 cell AdGaml (lanes 3, 7); cells infected with 10,000 particles/cell AdGaml (lanes 4, 8); no heat shock (lanes 1-4); heat shock (lanes 5-8). Duplicate blots were probed with antiserum to hsp40 (top panel) or tubulin (bottom panel).

It was found that Gaml expression also led to a modest increase of hsp40 (Fig. 1c) but not of hsp90 α , hsc70, or hsp27 (results not shown in the Figure.).

5 Example 2

Gaml expression relocates hsp70 to the nucleus in the absence of heat.

It is known that hsp70 moves to the nucleus following heat shock^{15,16}. Using immunofluorescence, the cellular

10 localization of hsp70 in cells expressing Gaml was monitored (Fig. 2a-i).

In the experiments shown in Figure 2, panels a-i show an immunofluorescence analysis of A549 cells that were noninfected (panels a, b, c); infected with AdGaml

15 (10,000 particles per cell; panels d, e, f) or with AdGFP (10,000 particles per cell; panels g,h,i), staining with anti-hsp70 (panels a, d and g), staining with anti-myc antibody for myc-tagged Gaml

(panels b, e) or GFP expression (panel h) or staining

20 for DNA (panels c, f and i). In panel f, the arrows indicate cells with high Gaml expression and nuclear accumulation of hsp70; the arrowhead indicates a cell with no detectable Gaml expression and no nuclear accumulation of hsp70.

25 Non-infected A549 cells present a predominantly cytoplasmic hsp70 distribution (Fig. 2a-c). Like heat shock, Gaml expression causes relocalization of hsp70 to the nucleus (Fig. 2d-f). Infection of cells with a control adenovirus expressing GFP in both cytoplasmic

and nuclear compartments causes no change in hsp70 levels or localization (Fig. 2g-i).

Example 3

5 Both Hsp70 and hsp40 localization are influenced by Gaml expression.

Figure 3 shows an analysis of the subcellular localization of hsp70 and hsp40 in response to Gaml expression. A549 cells were infected with either a
10 control adenovirus (AdLuc) or AdGaml. Two days after infection cells were lysed, nuclei were harvested by centrifugation and extracted once with a 100 mM NaCl buffer (see Methods). Aliquots of the cytoplasmic fraction (C), 100 mM nuclear extract (N1), and
15 remaining nuclear material (N2) were analyzed by immunoblotting for the presence of hsp70 or hsp40. The Figure shows extracts from non-infected cells (lanes 1-3); from cells infected with control adenovirus (AdLuc) at 10,000 particles per cell (lanes 4-6); and
20 from cells infected with AdGaml at 10,000 particles per cell (lanes 7-9).

When monitored biochemically, there was an increase in hsp70 and hsp40 levels in the nuclear fractions from AdGaml infected cells but not from non-infected cells
25 nor from control virus-infected cells, where hsp40 and hsp70 are found almost exclusively in the cytoplasmic fraction (Fig. 3).

Example 4

Hsp70 is upregulated during CELO infection.

It was important to determine if hsp70 induction is part of a normal CELO infection process. Figure 4 shows 5 an immunofluorescence analysis of hsp70 levels in LMH cells staining with anti-hsp70 (panels a, d), staining with anti-CELO capsid (panels b, e) or staining for DNA (panels c, f). Cells were either noninfected (panels a, b, c) or infected with wild type CELO (100 particles 10 per cell; panels d, e, f).

Hsp70 levels were also found to increase during CELO replication in LMH cells (Fig. 4, compare a and d). The accumulation of hsp70 during infection is nuclear and perinuclear, while CELO capsid proteins appear to 15 accumulate primarily in perinuclear sites (compare d and e).

Example 5

Analysis of CELO AIM65 growth and complementation with 20 AdGaml.

To examine the requirement for Gaml in CELO replication a Gaml-negative CELO bearing a luciferase gene was prepared (CELO AIM65, see methods section) and the replication capacity of the encoded virus was analyzed.

25 The CELO AIM65 genome was transfected into LMH cells alone, or followed 24 hours later, by infection with 1000 particles per cell of AdGaml. After 5 days the

cells were harvested and assayed for luciferase activity. An additional culture was used to infect a fresh set of LMH cultures either alone, or with AdGaml. This harvest, luciferase assay and passage were repeated 5 every 5 days for 5 passages. The left panel shows the results from CELO AIM65 alone; the right panel shows the results from CELO AIM65 plus AdGaml. The luciferase activity (average of three cultures plus standard deviation) is indicated for each passage.

10 It becomes clear from the results that after passage 2, luciferase activity from CELO AIM65 is no longer detectable, indicating that virus replication is blocked in the absence of Gaml (Fig. 5, left panel). However, if Gaml was supplied from a second virus during the initial 15 transfection and subsequent passages, transduction of luciferase activity was obtained, indicating the production of infectious virus (Fig. 5, right panel). Thus it can be concluded that the Gaml gene is essential for virus replication and the Gaml can be supplied from 20 a second, unrelated virus to complement virus replication.

Example 6

Analysis of CELO AIM65 growth in chicken embryos.

25 The replication of CELO AIM65 was also assessed in chicken embryos, the natural site of CELO replication. The indicated particle numbers of either CELO AIM46 or CELO AIM65 were injected into the allantoic cavity of 9 day embryos. After a 4 day incubation at 37°C, the

- virus present in lysates of allantoic fluid was measured by luciferase transduction in 293 cells. Each value represents the average of at least 5 independent embryo infections with luciferase transduction measured in
- 5 triplicate for each embryo's allantoic fluid. In independent experiments, CELO AIM46 and CELO AIM65 were found to have equal luciferase transduction activity (per viral particle) in 293 cells with 1×10^8 virus units per egg corresponding to 300 μg of purified virus.
- 10 Embryos were inoculated with either CELO AIM46 or with CELO AIM65. Five days later, allantoic fluid was harvested and assayed for infectious virus. CELO AIM46 produces a maximum yield of virus with inocula of 4×10^1 particles and higher (Fig. 6). In contrast,
- 15 comparable levels of CELO AIM65 replication was only observed with inocula of 4×10^7 particles and above (Fig. 6). Thus it could be shown that Gaml is required for CELO replication both in LMH cells and in chicken embryos.

20

Example 7

Complementation of CELO AIM65 growth by heat shock.

The previous experiments demonstrate that Gaml expression affects the levels and localization of hsp40 and hsp70 and that Gaml expression is essential for

25 CELO replication. These observations raise the possibility that increasing the levels of hsp70 and hsp40 might be a necessary function of Gaml during CELO replication. To address this question directly, it was

determined if a heat shock sufficient to elevate hsp70 and hsp40 could replace Gam1 in CELO replication.

- The genomes of CELO AIM46 or CELO AIM65 were transfected into LMH cells with AdGam1 added to one of
- 5 the CELO AIM65 cultures to complement the Gam1 defect as in Example 5. On the second day, one sample of each type of culture was exposed to 45°C for 90 minutes.
- After four days at 37°C, lysates were prepared, tested for luciferase activity, and then aliquots of the
- 10 lysates were added to fresh monolayers of LMH cells with the same series of test complementations (+/- heat shock, +/- AdGam1). This procedure was repeated for multiple passages; Fig. 7 shows luciferase data obtained from Passage 6 and Passage 7.
- 15 Similar to the results shown in Fig. 5, CELO AIM65 does not replicate, and the missing Gam1 function can be provided *in trans* by AdGam1. A short exposure of the infected cells to 45°C effectively complements the Gam1 defect similarly to AdGam1 complementation (Fig. 7,
- 20 compare lanes 2 and 3). Thus, the essential Gam1 functions during CELO infection can be replaced by a heat shock.

Example 8

- 25 Complementation of CELO AIM65 growth in by heat shock in a single round of infection.

Heat shock complementation was used to amplify a CELO AIM65 culture for purification of the virus on CsCl

gradients. Purified CELO AIM65 virus was then compared to CELO AIM46 in a single cycle of virus replication.

LMH cells were infected with either CELO AIM46 and CELO AIM65. The cells were either incubated at 37°C for

5 4 days (d lanes 1-3; e lanes 1, 2) or exposed to a
90 minute, 45°C heat shock either 24 hours before
infection (d lanes 4-6; e lanes 3, 4); 24 hours after
the infection (d lanes 7-9, e lanes 5, 6); or 2 hours
before infection (d lanes 10-12; e lanes 7, 8). After
10 4 days at 37°C, lysates of the cells were prepared and
equal aliquots analyzed by immunoblotting for the
presence of CELO capsid proteins (upper panel) or tested
for the ability to transduce the luciferase gene into
fresh LMH cells (lower panel).

15 The production of CELO AIM65, which was almost
undetectable in non-heated cultures (Fig. 8a, lane 3;
8b, lane 2), was stimulated by the heat shock (Fig. 8a,
lanes 6, 9 and 12 and 8b, lanes 4, 6 and 8), with the
greatest stimulation observed when the heat shock was
20 applied 2 hours before virus infection (Fig. 8a,
lane 12; Fig. 8b, lane 8). Thus it becomes clear that in
a single round of virus replication, the essential
function of Gaml in viruys replication can be replaced
by a heat shock.

Example 9

Complementation of CELO AIM65 growth by hsp40 expression but not by hsp70.

LMH cells were infected with 1 virus particle/cell of
5 CELOAIM65 either alone or plus 10,000 particles/cell of AdEGFP, AdGaml, Adhsp40, or Adhsp70. For each passage, lysates were prepared 5 days post-infection, luciferase was measured (average of three measurements with a standard deviation indicated) and a fresh monolayer of
10 LMH cells was infected (plus the indicated second virus). It is clear from the data that AdGaml complements the missing Gaml functions in CELO AIM65. Passageable luciferase activity was obtained, indicating the formation of new infectious virus
15 particles. Slightly less initial activity was observed with Adhsp40 complementation, however, by passage number 5, the Adhsp40 complementation produced passageable luciferase activity comparable to the AdGaml complementation. Complementation with Adhsp70
20 did not produce passageable virus demonstrating that hsp70 alone is not sufficient to replace Gaml functions. Complementation with the control virus AdEGFP also failed, indicating that functions or gene expression from the adenovirus vector cannot replace
25 Gaml.

It is concluded from these results that one of the heat shock proteins known to be induced by Gaml expression, hsp40, can partially replace the functions of Gaml in CELO replication.

Example 10

Complementation of CELO growth by direct replacement of Gam1 with a hsp40 cDNA.

An alternate method of assessing the complementation is

5 to include the test gene within the genome of
CELOAIM65. This approach eliminates the possibility
that background gene expression from the adenovirus
vector used in the previous example could be
influencing the complementation process. Thus, the
10 CELOAIM65 genome was modified, replacing the
luciferase cassette (which had been inserted during the
disruption of the Gam1 coding region) with either an
hsp40 or an hsp70 expression cassette to produce
pCELOdGhsp40 and pCELOdGhsp70. Establishment of virus
15 growth was performed by linearizing the genomes with
SpeI and transfecting them into LMH cells. pCELOdGhsp40
readily generated replicating virus as evidenced by
cytopathic effect and subsequent growth and
purification of CELOdGhsp40. However, three independent
20 attempts to establish a CELOdGhsp70 virus culture
failed, indicating that direct complementation of Gam1
functions by hsp70 was not possible. This is consistent
with the complementation results shown in Example 9
with hsp40 but not hsp70 showing the capacity to
25 complement Gam1.

The growth of CELOdGhsp40 was compared directly with
the growth of CELOwt, and CELOAIM65. LMH cells were
infected with 5 particles/cell of CELOwt, CELOdG or
CELOdGhsp40. After 5 days at 37°C, equal quantities of

lysate protein were analyzed by immunoblotting for virus capsid proteins. It is observed that both CELOwt and CELOdGhsp40 generate a signal for the viral capsid proteins, indicating that both viruses have proceeded
5 in the replication cycle to activate late gene expression. The signal derived from CELOdGhsp40 is approximately 1/20 of signal observed with CELOwt, indicating that the complementation is not complete. CELOAIM65 produced no detectable viral late genes
10 products.

It can be concluded that hsp40 when directly expressed from the CELO genome is capable of partially replacing the functions of Gaml. This is consistent with the data presented in Example 9.

15

REFERENCES

1. Baker, A., M. Saltik, H. Lehrmann, I. Killisch, V.
5 Mautner, G. Lamm, G. Christofori, and M. Cotten.
1997. Gene Therapy 4: 773-782.
2. Bett A.J., W. Haddara, L. Prevec, F.L.Graham. 1994.
Proc Natl Acad Sci USA 91:8802-8806
3. Boussif O., F. Lezoualc'h, M.A. Zanta, M.D. Mergny,
10 D. Scherman, B. Demeneix, and J.-P.Behr. 1995.
Proc. Natl. Acad. Sci. U S A. 92: 7297-7301.
4. Caravokyri, C. and K.N. Leppard. 1995. J. Virol.
69: 6627-6633.
5. Chartier C., E. Degryse, M. Gantzer, A. Dieterle,
15 A. Pavirani, and M. Mehtali. 1996. J. Virol. 70:
4805-4810.
6. Chiocca, S., R. Kurzbauer, G.Schaffner, A. Baker,
V. Mautner, and M. Cotten. 1996. J. Virol. 70:
2939-2949.
- 20 7. Chiocca, S., A. Baker, and M. Cotten. 1997. J.
Virol. 71: 3168-3177.
8. Colby, W.W. and T.Shenk. 1981. J. Virol. 39:
977-980.
9. Cotten, M., E. Wagner, K.Zatloukal, and M.L.
25 Birnstiel. 1993. J. Virol. 67:3777-3785.

10. Cowen, B., B.W. Calnek, N.A. Menendez and R.F. Ball. 1978. Avian Diseases 22: 459-470.
11. Crouzet J., L. Naudin, C. Orsini, E. Vigne, L. Ferrero, A. Le Roux, P. Benoit, M. Latta, C, 5 Torrent, D. Branellec, P. Denefle, J.F. Mayaux, M. Perricaudet, and P. Yeh, 1997. Proc Natl Acad Sci USA 94: 1414-1419.
12. DeGregori J., G. Leone, A. Miron, L. Jakoi, and J.R. Nevins. 1997. Proc Natl Acad Sci USA 94: 10 7245-7250.
13. Degryse, E. 1996. Gene 170: 45-50.
14. de Wet J.R., K.V. Wood, M. DeLuca , D.R. Helinski, and S. Subramani. 1987. Mol Cell Biol 7:725-737.
15. Fisher K.J., H. Choi, J. Burda, S.J. Chen, and 15 J.M. Wilson 1996. Virology 217: 11-22.
16. Ghosh-Choudhury, G., Y. Haj-Ahmad, and F.L. Graham. 1987. EMBO J. 6: 1733-1739.
17. Gillen, J.R., D.K.Willis, and A.J.Clark. 1974. in Mechanisms in Genetic Recombination (R.F. Greil, 20 ed.) Plenum, New York, pp123-135.
18. Gluzman, Y., H. Reichl, and D. Solnick, 1982. Helper-free adenovirus type 5 vectors. p187-192. in Y. Gluzman (ed.) Eukaryotic Viral Vectors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 25 NY.
19. Graham F.L., J. Smiley, W.C. Russell, and R. Nairn. 1977. J. Gen. Virol. 36:59-74.

20. Grubb B.R., R.J. Pickles, H. Ye, J.R. Yankaskas,
R.N.Vick, J.F. Engelhardt, J.M. Wilson,
L.G.Johnson, and R.C. Nature 371: 802-806.
21. Hardy S., M. Kitamura, T. Harris-Stansil, Y. Dai,
5 M.L.Phipps. 1997. J Virol 71: 1842-1849.
22. Hay, R.T., N.D. Stow, and I.M. McDougall. 1984. J.
Mol. Biol. 175: 493-510.
23. He T.C., S. Zhou, L.T. da Costa, J. Yu, K.W.
Kinzler, and B.A. Vogelstein. 1998. Proc Natl Acad
10 Sci USA 95:2509-2514.
24. Hess, M., A. Cuzange, R.W.H. Ruigrok, J. Chroboczek
and B. Jacrot. 1995. J. Mol. Biol. 252:379-385.
25. Horwitz, M.S. 1996. Adenoviruses. pp2149-2171 in
Fields Virology, Third Edition. edited by B.N.
15 Fields, D.M. Knipe, P.M. Howley et al., Lippincott-
Raven Publishers, Philadelphia.
26. Hunt, C. & Morimoto, R.I. Conserved features of
eukaryotic hsp70 genes revealed by comparison with
the nucleotide sequence of human hsp70. Proc. Natl.
20 Acad. Sci. U.S.A. 82, 6455-6459 (1985)
27. Imler J.L., C. Chartier, A. Dieterle, D. Dreyer, M.
Mehtali, and A. Pavirani. 1995. Gene Ther. 2: 263-
268.
28. Kawaguchi T., K. Nomura, Y. Hirayama, T. Kitagawa.
25 1987. Cancer Res. 47: 4460-4464.

29. Karlsson S., R.K. Humphries, Y.Gluzman, and A.W.Nienhuis. 1985. Proc Natl Acad Sci USA 82: 158-162.
30. Khatri A., Z.Z. Xu, and G.W. Both. 1997. Virology 239: 226-237.
31. Klonjkowski B., P. Gilardi-Hebenstreit, J. Hadchouel, V. Randrianarison, S. Boutin, P. Yeh , M. Perricaudet, and E.J. Kremer. 1997. Hum. Gene Ther. 8: 2103-2115
- 10 32. Kovacs I., D.E. Brough, J.T. Bruder, and T.J. Wickham. 1997. Curr. Opin. Biotechnol. 8: 583-589
33. Kumar-Singh R., and J.S. Chamberlain. 1996. Hum Mol Genet 5: 913-921.
- 15 34. Laver, W.G., H.B. Younghusband and N.G. Wrigley. 1971. Virology 45: 598-614.
35. Lemay P., M.L. Boudin, M. Milleville, and P. Boulanger. 1980. Virology 101: 131-143.
36. Li, P., A.J.D. Bellett and C.R. Parish. 1984a. J. Gen. Virol. 65: 1803-1815.
- 20 37. Li, P., A.J.D. Bellett and C.R. Parish. 1984b. J. Virol. 52: 638-649.
38. Li, P., A.J.D. Bellett and C.R. Parish. 1984c. J. Virol. 65: 1817-1825.
39. Lieber A., C.Y. He, I. Kirillova, and M.A. Kay. 25 1996. J Virol 70: 8944-8960.

40. McFerran, J.B. and B.M. Adair. 1977. Avian Pathology 6: 189-217.
41. Michou, A.-I., Lehrmann, H., Saltik, M. & Cotten, M. Mutational analysis of the avian adenovirus 5 CELO, which provides a basis for gene delivery vectors. *J. Virol.* 73, 1399-1410 (1999).
42. Mittal S.K., L. Prevec, F.L. Graham, and L.A. Babiuk. 1995.. *J. Gen. Virol.* 76:93-102.
43. Miyake S., M. Makimura, Y. Kanegae, S. Harada, Y. 10 Sato, K. Takamori, C. Tokuda, and I. Saito. 1996. *Proc Natl Acad Sci USA* 93: 1320-1324.
44. Oliner, J. D., K.W. Kinzler, and B. Vogelstein. 1993. *Nucleic Acids Research* 21: 5192-5197.
45. Ohtsuka K. Cloning of a cDNA for heat-shock protein 15 hsp40, a human homologue of bacterial DnaJ. *Biochem. Biophys. Res. Commun.* 197, 235-40 (1993) .
46. Parks R.J., L. Chen, M. Anton, U. Sankar, M.A. Rudnicki, F.L.Graham. 1996. *Proc Natl Acad Sci USA* 93: 13565-13570.
- 20 47. Petersson, U. and R.J. Roberts. 1986. Adenovirus gene expression and replication: a historical review. in DNA Tumor Viruses: Control of Gene Expression and Replication pp 37-57.Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 25 New York.

48. Plank C., K. Zatloukal, M. Cotten, K. Mechtler, and E. Wagner. 1992. *Bioconjugate Chemistry*. 3: 533-539.
49. Polyak K., Y. Xia, J.L. Zweier, K.W. Kinzler, and B. Vogelstein. 1997. *Nature* 389: 300-305.
50. Robinson A.J., H.B. Younghusband, and A.J. Bellett. 1973. *Virology* 56:54-69.
51. Schaack J., S. Langer, X. Guo. 1995. *J Virol.* 69: 3920-3923.
- 10 52. Shenk, T. 1995. Group C adenovirus as vectors for gene therapy. pp 2111-2148 in *Viral Vectors* (eds. M.G. Kaplitt and A.D. Loewy) pp. 43-54. Academic Press, San Diego.
- 15 53. Shenk, T. 1996. Adenoviridae: The viruses and their replication. in *Fields Virology*, Third Edition. edited by B.N. Fields, D.M. Knipe, P.M. Howley et al., Lippincott-Raven Publishers, Philadelphia.
54. Soberon X., L. Covarrubias, F. Bolivar. 1980. *Gene* 9: 287-305.
- 20 55. Van Doren K., D. Hanahan, and Y. Gluzman. 1984. *J Virol.* 50: 606-614.
56. Vrati S., E.S. Macavoy, Z.Z. Xu, C. Smole, D.B. Boyle, and G.W. Both. 1996b, *Virology* 220: 200-203.
- 25 57. Weiss R.S., S.S. Lee, B.V. Prasad, and R.T. Javier. 1997. *J. Virol.* 71:1857-1870.

58. Wilson C., and M.A. Kay. 1995. *Nature Medicine*. 1: 887-889.
59. Xu Z.Z., A. Hyatt, D.B. Boyle and G.W. Both. 1997. *Virology* 230: 62-71.
- 5 60. Yates, V.J. and D.E. Fry. 1957. *Am. J. Vet. Res.* 18: 657-660.
61. Zabner J., B.G. Zeiher, E. Friedman, and Welsh M.J. 1996. *J.Viro*. 70: 6994-7003.
- 10 62. Zabner J., P. Freimuth, A. Puga, A. Fabrega, and Welsh MJ. 1997. *J. Clin. Invest.* 100: 1144-1149.
63. Zheng B., S.K. Mittal, F.L. Graham, and L. Prevec. 1994. *Virus Res* 31: 163-186
64. Lillehoj H.S., and Trout J.M., 1996, *Clin. Microbiol. Rev.*, Jul. 9(3): 349-360
- 15 65. Taylor M.A., and Catchpole J. 1994, *Appl. Parasitol*, Jun. 35(2): 73-86
66. Shirley M.W., 1992, *Br. Vet. J.*, Nov. 148(6): 479-499
67. Lasher H.N. and Davis V.S., 1997, *Avian Dis.*, Jan. 41(1): 11-19
- 20 68. Buge S.L., Richardson E., Alipanah S., Markham P., Cheng S., Kalyan N., Miller C.J., Lubeck M., Udem S., Eldridge J., Robert-Guroff M., 1997, *J Virol* Nov;71(11):8531-41
- 25 69. Celli G., LaRochelle W.J., Mackem S., Sharp R., Merlino G., 1998, *EMBO J.* Mar 16;17(6):1642-55

70. de Quinto S.L., Martinez-Salas E., 1998, Gene Sep 14;217(1-2):51-6
71. Gerber H.P., Hillan K.J., Ryan A.M., Kowalski J., Keller G.A., Rangell L., Wright B.D., Radtke F.,
5 Aguet M., Ferrara N., 1999, Development Mar;126(6):1149-59
72. Gerdts V., Jons A., Makoschey B., Visser N., Mettenleiter T.C., 1997, J Gen Virol Sep;78 (Pt 9):2139-46
- 10 73. Havenga M.J.E., Vogels R., Braakman E., Kroos N., Valerio D., Hagenbeek A., van Es H.H.G., 1998, Gene Nov 19;222(2):319-27
74. Levenson V.V., Transue E.D., Roninson I.B., 1998, Hum Gene Ther May 20;9(8):1233-6
- 15 75. Li X., Wang W., Lufkin T., 1997, Biotechniques Nov;23(5):874-8, 880, 882
76. Lubeck M.D., Natuk R., Myagkikh M., Kalyan N., Aldrich K., Sinangil F., Alipanah S., Murthy S.C., Chanda P.K., Nigida S.M. Jr., Markham P.D., Zolla-
20 Pazner S., Steimer K., Wade M., Reitz M.S. Jr., Arthur L.O., Mizutani S., Davis A., Hung P.P., Gallo R.C., Eichberg J., Robert-Guroff M., 1997, Nat Med Jun;3(6):651-8
77. Ohtsuka K. Cloning of a cDNA for heat-shock protein
25 hsp40, a human homologue of bacterial DNA J.
Biochem. Biophys. Res. Commun. 197, 235-40 (1993)

78. Plank C., Zatloukal K., Cotten M., Mechtler K., and Wagner E., 1992, Bioconjugate Chemistry. 3: 533-539.
79. Robbins A.K., Watson R.J., Whealy M.E., Hays W.W.,
5 Enquist L.W., 1986, J Virol May;58(2):339-47
80. Schreurs C., Mettenleiter T.C., Zuckermann F., Sugg N., Ben-Porat T., 1988, J Virol Jul;62(7):2251-7
81. Vermeulen A.N., 1998, Int J Parasitol
Jul;28(7):1121-30
- 10 82. Talsma H., et al., 1997, Int. J. of Pharmaceutics
157, 233-238
83. Michou, A.-I., Lehrmann, H., Saltik, M. and Cotten, M. 1999. Mutational analysis of the avian adenovirus CELO, which provides a basis for gene delivery vectors. *J. Virol.* 73, 1399-1410.
- 15 84. Stratford-Perricaudet, L.D., Makeh, I., Perricaudet, M. and Briand, P. 1992. Widespread long-term gene transfer to mouse skeletal muscles and heart. *J. Clin. Invest.* 90, 626-30.
- 20 85. Evan, G.I., Lewis, G. K., Ramsay, G. & Bishop, J.M. 1985. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. *Mol. Cell. Biol.* 5, 3610-3616.

Claims

1. Recombinant CELO virus or CELO virus DNA,
characterized in that it carries a modification of
5 the wild type CELO DNA that results in a complete
loss of Gaml expression or an inhibition of
functional Gaml expression.
2. The recombinant CELO virus or CELO virus DNA of
claim 1, characterized in that the region spanning
10 nt 37391-38239 of the CELO wild type virus genome
is completely or partially deleted or altered or
contains an insertion.
3. The recombinant CELO virus or CELO virus DNA of
claim 2, characterized in that the region spanning
15 nt 36818-37972 of the wild type CELO virus genome
is deleted.
4. The recombinant CELO virus or CELO virus DNA of
claim 1, characterized in that it contains a
modification in the Gaml transcriptional control
20 sequences.
5. The recombinant CELO virus or CELO virus DNA of
claim 1, characterized in that it further contains
a deletion of or within a region selected from the
regions spanning nt 41731-43684, nt 41523-43684,
25 nt 41002-43684 and nt 40065-43684.
6. The recombinant CELO virus or CELO virus DNA of
claim 1, characterized in that it further contains
a deletion spanning nt 794-1330.

7. The recombinant CELO virus DNA of claim 1 contained on a plasmid that can be replicated in prokaryotic or eucaryotic cells.
8. The recombinant CELO virus or CELO virus DNA of claim 1, characterized in that it contains a foreign DNA insertion in place of one or more deletions.
9. The recombinant CELO virus or CELO virus DNA of claim 8 characterized in that the foreign DNA encodes an antigen derived from an animal pathogen.
10. The recombinant CELO virus or CELO virus DNA of claim 9 characterized in that the pathogen is avian.
11. The recombinant CELO virus or CELO virus DNA of claim 8 characterized in that the foreign DNA encodes a human protein.
12. The recombinant CELO virus or CELO virus DNA of claim 11, characterized in that the DNA encodes a therapeutically active protein.
- 20 13. The recombinant CELO virus or CELO virus DNA of claim 12, characterized in the DNA encodes an immunostimulatory protein.
14. The recombinant CELO virus or CELO virus DNA of claim 13, characterized in that the immunostimulatory protein is a cytokine.

15. The recombinant CELO virus or CELO virus DNA of
claim 11, characterized in that the foreign DNA
encodes a tumor antigen or a fragment thereof.
16. The recombinant CELO virus or CELO virus DNA of
5 claim 11, characterized in that the foreign DNA
encodes an antigen derived from a human pathogen.
17. A method for producing the recombinant CELO virus
of claim 1, characterized in that the modification
of CELO virus DNA is carried out on plasmid-borne
10 CELO virus DNA and that the recombinant CELO virus
DNA is introduced into a host that supports virus
replication and the host is incubated under
conditions that allow amplification of the virus.
18. A method of claim 17 characterized by the following
15 steps
- a) carrying out the DNA modification on plasmid-
borne CELO virus DNA,
- b) introducing the recombinant CELO virus DNA into
a host cell that supports virus replication, said
20 host cell being a primary cell or a cell from an
immortalized cell line,
- c) exposing the cells to a heat shock treatment
before, simultaneously with or after step b),
- d) growing the cells for a period of time
25 sufficient to obtain the desired number of viruses.
19. The method of claim 18, characterized in that the
heat shock treatment comprises exposing the cells
to temperatures above 43°C for period of time
sufficient to complement the replication defect.

20. The method of claim 19, characterized in that the
cells are exposed to 45°C.
21. The method of claim 19, characterized in that cells
are exposed to the heat shock treatment for 30 -
5 120 minutes.
22. The method of claim 21, characterized in that cells
are exposed to the heat shock treatment for
90 minutes.
23. The method of claim 17 characterized in that the
10 host is an avian embryo which is infected with more
than 10^7 virus particles per embryo.
24. A method for producing the recombinant CELO virus
of claim 1 characterized by the following steps
a) carrying out the DNA modification on plasmid-
15 borne CELO virus DNA,
b) introducing the recombinant CELO virus DNA into
a host cell that supports virus replication, said
host cell being a primary cell or a cell from an
immortalized cell line,
c) exposing the cells to a heat shock treatment
before, simultaneously with or after step b),
d) growing the cells for a period of time
sufficient to obtain the desired number of viruses,
e) introducing the viruses obtained in d) into an
25 avian embryo at a number higher than 10^7 virus
particles per embryo and incubating the embryo for
a period of time sufficient to amplify the virus.
25. The method of claim 23, characterized in that the
embryo is chicken.

26. The method of claim 17, wherein the host cell carries a DNA from which hsp40 or another protein upregulated by Gam1 is expressed.
27. The method of claim 26, wherein the host cell carries a plasmid encoding hsp40 or another protein upregulated by Gam1.
28. The method of claim 26, wherein the host cell is coinfectected with a recombinant adenovirus directing the synthesis of hsp40 or another protein upregulated by Gam1.
29. The method of claim 26, wherein the host cell is infected with a CELO virus into whose genome an expression cassette encoding hsp40 or another protein upregulated by Gam1 has been inserted.
30. A vaccine against an infectious disease of an animal comprising CELO virus of claim 9.
31. A vaccine against an infectious disease of a bird comprising CELO virus of claim 10.
32. A vaccine against an infectious disease of a human comprising CELO virus of claim 16.
33. A pharmaceutical composition containing as an active ingredient a CELO virus of claim 12.
34. The CELO virus of claim 12 for the manufacture of a tumor vaccine.
35. Method for producing a recombinant protein of interest, characterized in that the recombinant

CELO virus of claim 8, wherein the foreign DNA encodes the protein of interest, is introduced into avian embryos at a number higher than 10^7 particles per embryo and the virus is allowed to amplify to 5 produce the protein of interest and the protein is recovered.

36. The method of claim 35, wherein DNA encoding the protein of interest is fused to a DNA molecule encoding an immunoglobulin Fc domain.
- 10 37. The method of claim 36, wherein the foreign DNA further comprises a signal sequence.
38. The method of claim 37, wherein the protein of interest is a secreted protein and the signal sequence is its natural signal sequence.
- 15 39. The method of claim 38, wherein the signal sequence is derived from a protein naturally secreted into chicken eggs, said protein being different from the protein of interest.
40. The method of claim 39, wherein the signal sequence 20 is derived from ovalbumin, avidin, conalbumin or lysozyme.

Abstract

5 Recombinant CELO virus or CELO virus DNA with a
deletion or disruption of the Gaml gene, optionally
combined with deletions at the right or left end of the
viral genome that allow insertion of large pieces of
foreign DNA. The virus is useful as a vaccine for
10 animals, in particular birds, and for gene therapy and
vaccine applications in humans. The virus can also be
used for recombinant protein production.

Fig. 1 A




Fig. 1 B




Fig. 1 C




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8 A




Fig. 8 B

